Skip to main content

Advertisement

SpringerLink
Log in

18F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value

  • Original Article
  • Published:
Japanese Journal of Radiology Aims and scope Submit manuscript

Abstract

Purpose

This study aimed to explore the clinical and prognostic significance of 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in epithelial ovarian cancer (EOC).

Methods

We retrospectively investigated 48 EOC patients who underwent preoperative 18F-FDG PET/CT and primary cytoreductive surgery at our hospital between January 2010 and June 2015. None of these patients received neoadjuvant chemotherapy. PET/CT parameters including the maximum and average standardized uptake value (SUVmax, SUVavg), the metabolic tumor volume (MTV) were measured. Tumor proliferation marker Ki67 was evaluated using immunohistochemistry. The relationships between the PET/CT parameters and chemosensitivity, tumor proliferation, and overall survival (OS) were analyzed, respectively.

Results

The median (range) SUVmax, SUVavg, and MTV values were 11.42 (3.14–20.20), 4.8 (2.55–9.47), and 150.11 (0.19–792.46), respectively. Overall, 93.8% (45/48) of patients had high-grade serous ovarian cancer. The SUVmax value had a positive correlation with the Ki67 index (P = 0.030, r = 0.314), and a higher SUVmax level was associated with chemosensitivity (P = 0.026). However, neither SUVavg nor MTV had associations with the patients’ clinicopathological parameters. None of these three PET/CT parameters were found to be potential predictors of OS.

Conclusions

Preoperative 18F-FDG PET/CT had a predictive value on chemosensitivity and proliferation after primary debulking surgery in EOC patients noninvasively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.

    Article  PubMed  Google Scholar 

  2. Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2015;131(Suppl 2):S111–22.

    Article  PubMed  Google Scholar 

  3. Risum S, Loft A, Hogdall C, Berthelsen AK, Hogdall E, Lundvall L, et al. Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer. Acta Oncol (Stockholm, Sweden). 2011;50(3):415–9.

    Article  Google Scholar 

  4. Nakamura K, Hongo A, Kodama J, Hiramatsu Y. The pretreatment of maximum standardized uptake values (SUVmax) of the primary tumor is predictor for poor prognosis for patients with epithelial ovarian cancer. Acta Med Okayama. 2012;66(1):53–60.

    PubMed  Google Scholar 

  5. Tanizaki Y, Kobayashi A, Shiro M, Ota N, Takano R, Mabuchi Y, et al. Diagnostic value of preoperative SUVmax on FDG-PET/CT for the detection of ovarian cancer. Int J Gynecol Cancer. 2014;24(3):454–60.

    Article  PubMed  Google Scholar 

  6. Konishi H, Takehara K, Kojima A, Okame S, Yamamoto Y, Shiroyama Y, et al. Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma. Int J Gynecol Cancer. 2014;24(7):1190–4.

    Article  PubMed  Google Scholar 

  7. Lee JW, Cho A, Lee JH, Yun M, Lee JD, Kim YT, et al. The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT in the prognosis of epithelial ovarian cancer. Eur J Nucl Med Mol Imaging. 2014;41(10):1898–906.

    Article  PubMed  Google Scholar 

  8. Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol. 2012;19(6):1966–72.

    Article  PubMed  Google Scholar 

  9. Fanfani F, Monterossi G, Fagotti A, Gallotta V, Costantini B, Vizzielli G, et al. Positron emission tomography–laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol. 2015;22(2):649–54.

    Article  PubMed  Google Scholar 

  10. Vargas HA, Burger IA, Goldman DA, Micco M, Sosa RE, Weber W, et al. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. Eur Radiol. 2015;25(11):3348–53.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Kitajima K, Suenaga Y, Ueno Y, Maeda T, Ebina Y, Yamada H, et al. Preoperative risk stratification using metabolic parameters of 18F-FDG PET/CT in patients with endometrial cancer. Eur J Nucl Med Mol Imaging. 2015;42(8):1268–75.

    Article  PubMed  CAS  Google Scholar 

  12. Yamamoto M, Tsujikawa T, Fujita Y, Chino Y, Kurokawa T, Kiyono Y, et al. Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy. Cancer Sci. 2016;107(4):478–85.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Kim CY, Jeong SY, Chong GO, Son SH, Jung JH, Kim DH, et al. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer. Gynecol Oncol. 2015;136(3):498–504.

    Article  PubMed  Google Scholar 

  14. Feng Z, Wen H, Bi R, Duan Y, Yang W, Wu X. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients. BMC Cancer. 2016;16:43.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Feng Z, Wen H, Ju X, Bi R, Chen X, Yang W, et al. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC). J Ovarian Res. 2017;10(1):7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Yang Z, Shi Q, Zhang Y, Pan H, Yao Z, Hu S, et al. Pretreatment 18F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma–a retrospective study. Radiat Oncol (London, England). 2015;10:4.

    Article  Google Scholar 

  17. Kurtipek E, Cayci M, Duzgun N, Esme H, Terzi Y, Bakdik S, et al. 18F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non-small cell lung cancer. Clin Nucl Med. 2015;40(6):459–63.

    Article  PubMed  Google Scholar 

  18. Lee HJ, Lee JJ, Park JY, Kim JH, Kim YM, Kim YT, et al. Prognostic value of metabolic parameters determined by preoperative 18F-FDG PET/CT in patients with uterine carcinosarcoma. J Gynecol Oncol. 2017;28(4):e43.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med. 2006;57:99–118.

    Article  PubMed  CAS  Google Scholar 

  20. Jager PL, de Korte MA, Lub-de Hooge MN, van Waarde A, Koopmans KP, Perik PJ, et al. Molecular imaging: what can be used today. Cancer Imaging. 2005;5 Spec No A:S27–32.

    Article  PubMed  CAS  Google Scholar 

  21. Bono Y, Mizumoto Y, Nakamura M, Iwadare J, Obata T, Fujiwara H. FDG-PET-positive ovarian thecoma with GLUT5 expression: five cases. J Obstet Gynaecol Res. 2017;43(3):599–603.

    Article  PubMed  Google Scholar 

  22. Del Gobbo A, Pellegrinelli A, Gaudioso G, Castellani M, Zito Marino F, Franco R, et al. Analysis of NSCLC tumour heterogeneity, proliferative and 18F-FDG PET indices reveals Ki67 prognostic role in adenocarcinomas. Histopathology. 2016;68(5):746–51.

    Article  PubMed  Google Scholar 

  23. Hu SL, Yang ZY, Zhou ZR, Yu XJ, Ping B, Zhang YJ. Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation. Nucl Med Commun. 2013;34(6):533–9.

    Article  PubMed  Google Scholar 

  24. Abgral R, Leboulleux S, Deandreis D, Auperin A, Lumbroso J, Dromain C, et al. Performance of 18fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≧ 10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab. 2011;96(3):665–71.

    Article  PubMed  CAS  Google Scholar 

  25. Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T, et al. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer (Tokyo, Japan). 2011;18(4):299–308.

    Article  Google Scholar 

  26. Onishi R, Noguchi M, Kaida H, Moriya F, Chikui K, Kurata S, et al. Assessment of cell proliferation in renal cell carcinoma using dual-phase 18F-fluorodeoxyglucose PET/CT. Oncol Lett. 2015;10(2):822–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-d-glucose uptake in A431 and T47D cells in culture. Cancer Res. 1999;59(18):4709–14.

    PubMed  CAS  Google Scholar 

  28. Tanimoto K, Yoshikawa K, Obata T, Ikehira H, Shiraishi T, Watanabe K, et al. Role of glucose metabolism and cellularity for tumor malignancy evaluation using FDG-PET/CT and MRI. Nucl Med Commun. 2010;31(6):604–9.

    PubMed  CAS  Google Scholar 

  29. Vallius T, Peter A, Auranen A, Carpen O, Kemppainen J, Matomaki J, et al. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Gynecol Oncol. 2016;140(1):29–35.

    Article  PubMed  Google Scholar 

  30. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005;23(30):7445–53.

    Article  PubMed  Google Scholar 

Download references

Funding

This work was funded by the project of the Science and Technology Commission of Shanghai Municipality for XH Wu (15411962000) and for ZX Jiang (15411968200).

Author information

Author notes

  1. Shuai Liu and Zheng Feng contributed equally to this work.

Authors and Affiliations

  1. Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China

    Shuai Liu & Herong Pan

  2. Center for Biomedical Imaging, Fudan University, Shanghai, China

    Shuai Liu & Herong Pan

  3. Shanghai Engineering Research Center of Molecular Imaging Probes, Fudan University, Shanghai, China

    Shuai Liu & Herong Pan

  4. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

    Shuai Liu, Zheng Feng, Hao Wen, Zhaoxia Jiang, Herong Pan, Xingzhu Ju, Xiaojun Chen & Xiaohua Wu

  5. Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, 270 Dong’an Road, Shanghai, 200032, China

    Zheng Feng, Hao Wen, Yu Deng, Lei Zhang, Xingzhu Ju, Xiaojun Chen & Xiaohua Wu

  6. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China

    Yu Deng & Lei Zhang

  7. Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China

    Zhaoxia Jiang

Authors
  1. Shuai Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zheng Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hao Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhaoxia Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Herong Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xingzhu Ju
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiaojun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xiaohua Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaohua Wu.

Ethics declarations

The ethics committee of our institution does not require patient consent for retrospective review of imaging studies.

Conflict of interest

The authors declare that they have no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, S., Feng, Z., Wen, H. et al. 18F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value. Jpn J Radiol 36, 544–550 (2018). https://doi.org/10.1007/s11604-018-0755-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11604-018-0755-y

Keywords

Search

Navigation